PRIMARY BREAST CANCER THERAPY GROUP

原发性乳腺癌治疗组

• 批准号: 3556973
• 负责人: NIKOLAY V DIMITROV
• 金额: $ 13.33万
• 依托单位: MICHIGAN STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-12-12 至 1991-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556973
• 关键词: Corynebacterium; antineoplastic antibiotics; breast neoplasms; breast surgery; combination cancer therapy; combination chemotherapy; cooperative study; doxorubicin; estrogen inhibitor; estrogens; fluorouracil; human subject; human therapy evaluation; longitudinal human study; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; rectum neoplasms; tamoxifen

As participating institution in the primary breast cancer therapy group (NSABP), we have contributed data from patients entering various protocols, and will continue to contribute data to protocols B-06, 11, 12, 13, 14, C-01 and R-01. The present application seeks funding: (a) to permit continued patient accrual in on-going protocols; (b) to participate in the NSABP activities relating to evaluation and execution of the present trials, design of new protocols, planning for the future, education for increase of patient accrual and cooperation with the headquarters; (c) participation in clinical research accepted by NSABP and particularly clinical investigation related to the effect of adjuvant treatment on our own patients; (4) investigating factors that affect compliance with therapeutic regimen. Though follow-up of all patients on various protocols will be an essential activity as well. Protocol B-06 is a trial to compare the worth of segmental mastectomy with total mastectomy. Our efforts will be directed toward those community hospitals and oncology teams which have not contributed patients to this very important study. We have made a plan to hold workshops every four months which will introduce the community surgeons to the required techniques. Protocols B-11 and 12 evaluate patients with breast cancer Stage II using more aggressive treatment. In this trial we are performing special evaluations of the patients receiving Adriamycin. A cardiology team will evaluate every patient on this drug before treatment and thereafter at periodic intervals using non-invasive techniques. This is of great importance because of the excellent performance status of our patients which may be altered by unexpected cardiotoxicity. Protocols B-13 and 14 will study patients with Stage I and treatment -vs- no treatment will be tested according to their ER status. We will continue to make a substantial contribution as in the past to the adjuvant protocols for primary colo-rectal carcinoma. Finally, an aim of this protocol is to increased the multidisciplinary approach of our institution in clinical trials, and to involve as many community physicians as possible to enhance patient accrual and to create an environment essential to the gathering of important biological data on breast and bowel cancer.

作为乳腺癌初级治疗组的参与机构 (NSABP)，我们提供了输入各种协议的患者的数据， 并将继续为协议B-06、11、12、13、14贡献数据， C-01 和 R-01。 本申请寻求资金： (a) 允许 在正在进行的方案中持续增加患者； (b) 参加 NSABP 与当前评估和执行相关的活动 试验、新方案设计、未来规划、教育 增加患者数量以及与总部的合作； (三) 参与 NSABP 接受的临床研究，特别是 与辅助治疗对我们的影响相关的临床研究 自己的病人； (4)调查影响遵守的因素 治疗方案。 通过各种方案对所有患者进行随访 也将是一项重要的活动。 方案 B-06 是一个比较试验 部分乳房切除术与全乳房切除术的价值。 我们的努力将 针对那些有过相关经历的社区医院和肿瘤团队 没有为这项非常重要的研究贡献患者。 我们已经制定了计划 每四个月举办一次研讨会，介绍社区 外科医生掌握所需的技术。 方案 B-11 和 12 评估 II期乳腺癌患者使用更积极的治疗。 在 在这项试验中，我们正在对接受治疗的患者进行特殊评估 阿霉素。 心脏病学团队将评估每位患者服用该药物的情况 治疗前和治疗后定期使用非侵入性 技术。 这一点非常重要，因为它具有出色的 我们患者的表现状态可能会因意外而改变 心脏毒性。 方案 B-13 和 14 将研究 I 期和 将根据他们的 ER 状态对治疗与不治疗进行测试。 我们将一如既往，继续为世界经济作出巨大贡献 原发性结直肠癌的辅助方案。 最后的一个目标是 该协议旨在增强我们的多学科方法 机构参与临床试验，并让尽可能多的社区医生参与 尽可能提高患者获益并创造环境 对于收集有关乳房和肠道的重要生物学数据至关重要 癌症。